Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00131144
Status:
COMPLETED
Last Update Posted:
2011-11-17
First Post:
2005-08-16
Brief Title:
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Randomized Controlled Study on the Efficacy and Safety of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferate Diabetic Retinopathy NPDR or Low Risk Proliferative Diabetic Retinopathy PDR
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The most common ocular disease in patients with diabetes diabetic retinopathy is present in approximately 40 of diabetic patients about 8 of diabetic patients have vision threatening diabetic retinopathy Although intensive control of blood glucose has been shown to reduce the development and progression of diabetic retinopathy intensive control of glucose is usually not achieved in clinical practice
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None